Scarica l'app Stockscreener
1.93
0.00%
0.00
Dopo l'orario di chiusura:
1.93
Precedente Chiudi:
$1.93
Aprire:
$1.97
Volume 24 ore:
290.14K
Relative Volume:
0.62
Capitalizzazione di mercato:
$53.56M
Reddito:
$50,000
Utile/perdita netta:
$-41.60M
Rapporto P/E:
-1.1389
EPS:
-1.6946
Flusso di cassa netto:
$-20.20M
1 W Prestazione:
-4.93%
1M Prestazione:
-17.87%
6M Prestazione:
+59.50%
1 anno Prestazione:
-9.81%
Intervallo 1D:
$1.93
$1.9987
Intervallo di 1 settimana:
$1.88
$2.045
Portata 52W:
$1.09
$2.60
Inmune Bio Inc Stock (INMB) Company Profile
Nome
Inmune Bio Inc
Settore
Industria
Telefono
(858) 964-3720
Indirizzo
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.93 | 56.34M | 50,000 | -41.60M | -20.20M | -1.6946 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-01 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-21 | Iniziato | Alliance Global Partners | Buy |
| 2024-09-27 | Iniziato | Raymond James | Outperform |
| 2024-08-22 | Iniziato | Scotiabank | Sector Outperform |
| 2023-06-01 | Iniziato | Robert W. Baird | Outperform |
| 2022-05-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
| 2021-04-21 | Iniziato | B. Riley Securities | Buy |
| 2021-01-22 | Reiterato | Maxim Group | Buy |
| 2020-09-01 | Iniziato | BTIG Research | Buy |
| 2020-07-15 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Inmune Bio Inc Borsa (INMB) Ultime notizie
Form 4 INmune Bio Inc For: 23 September - Investing.com India
Form 4 INmune Bio Inc For: 23 September By Investing.com - Investing.com Canada
Inmune Bio (INMB) gives director 3-year option grant - Stock Titan
[Form 3] Inmune Bio, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Inmune Stock Price Forecast. Should You Buy INMB? - StockInvest.us
Inmune Bio (NASDAQ: INMB) grants 100,000 stock options to new director - Stock Titan
New Inmune Bio (INMB) director reports no shares - Stock Titan
Inmune Bio Adds Strategic Directors to Support Commercialization - TipRanks
INmune Bio, Inc. Announces Board Appointments - marketscreener.com
INmune Bio at H.C. Wainwright conference: rdeB drug nears filings By Investing.com - Investing.com Canada
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board - Yahoo Finance
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits
INmune Bio to Present at the H.C. Wainwright Global Investment Conference - Yahoo Finance
INmune Bio Inc (INMB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inmune Bio stock steadies as investors await next data catalyst - ad-hoc-news.de
INmune Bio undervalued as Ebstrocel for RDEB ne... - Pluang
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment (NASDAQ:INMB) - Seeking Alpha
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - Sahm
INmune Bio submits EU regulatory filings for Ebstrocel in RDEB By Investing.com - Investing.com Canada
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings - Yahoo Finance
INmune Bio (INMB) Climbs 4.33% to $2.17 as Traders Test Key Resistance at $2.28Put Spread Alert - dars.gov.et
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio (INMB) Q2 2026 Earnings Call Transcript - AOL.com
INmune Bio Advances Ebstrocel Regulatory Filings and Clinical Plans - sekbernews.id
INmune Bio (NASDAQ:INMB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Q2 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
Earnings call transcript: INmune Bio posts narrower Q2 2026 loss, eyes filings - Investing.com South Africa
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress - The Manila Times
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regula - GuruFocus
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ... - Yahoo Finance
INmune Bio, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
INmune Bio Q2 Earnings Call Highlights - MarketBeat
INmune Bio Q2 2026 Earnings: Tax-Credit Benefit Narrows Net Loss - TradingKey
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.16 EPS - MarketBeat
INMB: Ebstrocel nears global filings as financials strengthen and XPro advances in Alzheimer's - TradingView
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Inmune Bio, Inc. Q2 2026: Revenue $0 Net loss $(1.27)M, EPS $(0.05) — 10-Q Summary - TradingView
INmune Bio Q2 net loss narrows on lower impairment charges - TradingView
INmune Bio (NASDAQ: INMB) posts $6.7M loss and warns on cash runway - Stock Titan
10-Q: INmune Bio | 10-Q: Q2 2026 Earnings Report - Moomoo
INmune Bio Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
INmune Bio receives $4.6M in R&D rebates from Australia, UK - Investing.com UK
INmune Bio Strengthens Cash Runway With R&D Rebates - TipRanks
INmune Bio receives ~$4.6M in R&D rebates, cash proceeds exceed Q2 operating cash use - TradingView
INmune Bio (INMB.US) will release its earnings report after market close on August 6. - moomoo.com
INmune Bio Inc.Common stock (INMB) Stock Price, News, Quote & History - FinancialContent
INmune Bio Receives $4.2 Million Australia R&D Rebate, Extending Cash Runway for CORDStrom Development - Quiver Quantitative
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on ... - Caledonian Record
INmune Bio schedules Aug. 6 webcast on second-quarter results - Stock Titan
INmune Bio forms scientific advisory board for cell therapy By Investing.com - Investing.com Nigeria
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform - Yahoo Finance
Inmune Bio Inc Azioni (INMB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Inmune Bio Inc Azioni (INMB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lowdell Mark William | Chief Scientific Officer |
Jul 02 '26 |
Option Exercise |
1.40 |
7,211 |
10,095 |
1,518,017 |
| Moss David J | Chief Executive Officer |
Jul 02 '26 |
Option Exercise |
1.40 |
9,014 |
12,620 |
1,294,883 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):